ANABIOTICASubmit a source Research.
This category follows ideas being studied for aging itself. Mechanistic promise, animal lifespan extension, and biomarker movement can justify research, but none alone proves that an intervention extends healthy human life.
11 evidence-ranked entriesWhat the evidence cannot settle yet
Most entries lack randomized human aging outcomes, use small or disease-specific samples, or depend on surrogate endpoints. The strongest current rating in this category can still fall below the strongest rating elsewhere in the library.
Risks depend on the intervention
Long-term safety in healthy people is often unknown. Unapproved drugs, gene therapies, transfusions, and self-experimentation can introduce risks that early efficacy studies are too small or short to measure.
Moderate evidence leads this category
Ratings compare confidence in each entry's stated benefit—not whether every intervention is appropriate or recommended.
How ratings workEvery research entry
Sorted from stronger to weaker evidence.
Caloric Restriction
Sustained energy reduction without malnutrition that improves several cardiometabolic markers in non-obese adults but has not been shown to extend human lifespan.
NAD+ Precursors
Nicotinamide riboside and NMN reliably alter NAD-related biomarkers, but human trials have not established broad improvements in function, disease prevention, or longevity.
Acarbose for Longevity
A prescription carbohydrate-absorption drug that extends lifespan in mice and delays diabetes in some high-risk humans, without evidence that it extends human life.
Taurine for Longevity
An amino-sulfonic acid with striking animal-aging results and modest cardiometabolic trial signals, but conflicting human biomarker data and no lifespan evidence.
Rapamycin
An mTOR inhibitor with compelling animal longevity data but no established anti-aging benefit in healthy humans.
Senolytics
Experimental compounds intended to remove senescent cells, with intriguing biology but only tiny early human studies.
Metformin
A foundational diabetes medicine and prominent geroscience candidate whose observational longevity signals have not become proof of slower aging in healthy people.
Partial Cellular Reprogramming
A frontier gene-therapy strategy that can reset selected aging signals in animals and has only just entered localized first-in-human safety testing.
Resveratrol
A heavily studied polyphenol with compelling laboratory biology but no clinical proof of slower human aging or longer life.
Spermidine
A dietary polyamine linked to autophagy in laboratory models, with early human trials that have not established cognitive, anti-aging, or longevity benefits.
Young-Donor Plasma
An unapproved anti-aging intervention extrapolated from animal parabiosis, with no demonstrated clinical benefit and real transfusion-related risks.